Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals

International Journal of Cardiology

Volumn 68, Issue 3, 1999, Pages 309-316

  Ergin, Ali ^a   Abaci, Adnan ^a   Sakalli, Ahmet ^a   Kemal Eryol, Namik ^a   Oǧuzhan, Abdurrahman ^a   Ünal, Şükrü ^a   Çetin, Servet ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Acute myocardial infarction; Pharmacology; Therapy; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG USE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; Q WAVE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; FEMALE; HEPARIN; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITROGLYCERIN; PLATELET AGGREGATION INHIBITORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TURKEY; VASODILATOR AGENTS;

EID: 0033559781     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00369-6     Document Type: Article

References (33)

1. ACC/AHA Task Force Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular procedures (Subcommittee to Develop Guidelines for the Early Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol. 16:1990;249-292.
2. ACC/AHA Task Force Guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 28:1996;1328-1428.
3. Califf R.M., Topol E.J., Gersh B.J. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol. 14:1989;1382-1388.
4. Muller D.W.M., Topol E.J. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med. 113:1990;949-960.
5. Grines C.L., DeMaria A.N. Optimal utilization of thrombolytic therapy for acute myocardial infarction: concept and controversies. J Am Coll Cardiol. 16:1990;223-231.
6. Kennedy J.W. Expanding the use of thrombolytic therapy for acute myocardial infarction. Ann Intern Med. 113:1990;907-908.
7. Antman E.M., Lau J., Kupelnick B., Mosteller F., Chalmers T.C. A comparison of results of meta-analysis of randomized controlled trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA. 268:1992;240-248.
8. Lau J., Antman E.M., Jimenez-Silva J., Kupelnick B., Mosteller F., Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. New Engl J Med. 327:1992;248-254.
9. Pashos C.L., Normand S.L.T., Garfinkle J.B., Newhouse J.P., Epstein A.M., McNeil B.J. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol. 23:1994;1023-1030.
10. Phillips B.G., Yim J.M., Brown E.J. Jr.et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J. 131:1996;872-878.
11. Rogers W.J., Bowlby L.J., Chandra N.C.et al. (For the Participants in the National Registry of Myocardial Infarction). Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the national registry of myocardial infarction. Circulation. 90:1994;2103-2114.
12. Rustige J., Schiele R., Burczyk U.et al. The 60 minute Myocardial Infarction Project. Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J. 18:1997;1438-1446.
13. European Secondary Prevention Study Group Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet. 347:1996;1203-1207.
14. Jagger J.D., Murray R.G., Davies M.K., Littler W.A., Flint E.J. Eligibility for thrombolytic therapy in acute myocardial infarction. Lancet. 1:1987;34-35.
15. Doorey A.J., Michelson E.L., Topol E.J. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises. JAMA. 268:1992;3108-3114.
16. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 343:1994;1115-1122.
17. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 345:1995;669-685.
18. Fibrinolytic Therapy Trialists (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 343:1994;311-322.
19. Krumholz H.M., Pasternak R.C., Weinstein M.C.et al. Cost effectiveness of thrombolytic therapy in elderly patients with suspected acute myocardial infarction. New Engl J Med. 327:1992;7-13.
20. The TIMI IIIB Investigators Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation. 89:1994;1545-1556.
21. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 260:1988;2088-2093.
22. Beta-Blocker Heart Attack Trail Research Group A randomized trial of propranolol on patients with acute myocardial infarction. JAMA. 247:1982;1707-1714.
23. The Israeli SPRINT Study Group Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 9:1988;354-364.
24. Sirnes P.A., Overskeid K., Pedersen T.R.et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation. 70:1984;638-644.
25. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction. New Engl J Med. 319:1988;385-392.
26. Pfeffer M.A., Braunwald E., Moye L.A.et al. (On behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction - results of the survival and ventricular enlargement trial. New Engl J Med. 327:1992;669-677.
27. Yim J.M., Hoon T.J., Bittar N.et al. Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction. Am J Cardiol. 75:1995;1184-1186.
28. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 2:1988;349-360.
29. Bussmann W.D., Passek D., Seidel W., Kaltenbach M. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation. 63:1981;615-622.
30. Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage and infarct location. Circulation. 78:1988;906-919.
31. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
32. Sacks F.M., Pfeffer M.A., Moye L.A.et al. (For the Cholesterol and recurrent events trial investigators). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 335:1996;1001-1009.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 23:1993;3015-3023.